Literature DB >> 229054

Cytostatic activity of peripheral blood monocytes against bronchogenic carcinoma cells in patients with lung cancer.

E Yanagawa, K Yasumoto, H Manabe, N Nagano, N Hirota, M Ohta, T Hattori, K Nomoto, I Azuma, Y Yamamura.   

Abstract

Cytostatic acitivity of peripheral blood monocytes against cultured cell lines of bronchogenic carcinoma was examined in patients with lung cancer. Cytostatic activity in lung cancer patients with neither augmented nor suppressed as compared with that of controls such as normal healthy persons, patients with malignancies other than lung cancer, and patients with benign respiratory diseases. There was no correlation between the cytostatic activity of monocytes and the advance of clinical stages of the disease. Conventional modalities of anticancer treatments such as surgery, radiotherapy, chemotherapy, and their combination therapy had no effect on cytostatic activity of peripheral blood monocytes. However, adequate immunotherapy with nocardia rubra cell-wall skeleton augmented the cytostatic activity of peripheral blood monocytes, although adequate immunotherapy with Mycobacterium bovis BCG cell-wall skeleton had no effect.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 229054

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  3 in total

1.  Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients.

Authors:  S Sone; T Utsugi; P Tandon; H Yanagawa; A Okubo; T Ogura
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Studies of serum-free medium for the generation of lymphokine-activated killer cells.

Authors:  M Togami; K Yasumoto; T Yano; T Ishida; G Kimura; K Sugimachi; K Nomoto
Journal:  Cytotechnology       Date:  1991-05       Impact factor: 2.058

3.  Natural cytotoxicity of lymphocytes and monocytes and its augmentation by OK432 in melanoma patients.

Authors:  E Yanagawa; A Uchida; E M Kokoschka; M Micksche
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.